ANIP
ANI Pharmaceuticals, Inc.$72.00-0.85 (-1.17%)Prev Close$73.16·MCap$1.65B·P/E18.35·Vol131.8K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
56
$23.20M
◆
Net Activity
Net Seller
$23.20M
●
Active Insiders
13
last 12 mo
Over the past 12 months, insider activity at ANI Pharmaceuticals, Inc. (ANIP) has been exclusively selling, with 0 insider purchases totaling $0.00 and 56 insider sales totaling $23.20M. The most recent insider transaction was by CAREY STEPHEN P. (officer: SVP & CFO), who sold $207.7K worth of shares on Oct 30, 2026. ANI Pharmaceuticals, Inc. operates in the Healthcare sector, within the Drug Manufacturers - Specialty & Generic industry, with a market cap of $1.65B.
ANIP Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $72.87 | $207.7K | 166,143 |
| Oct 16, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 5,400 | $71.89 | $388.2K | 333,689 |
| Oct 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $73.59 | $36.8K | 73,424 |
| Sep 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $73.00 | $208.1K | 168,993 |
| Sep 16, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 5,400 | $71.00 | $383.4K | 339,089 |
| Sep 14, 2026 | Thoma Jeanne | director | Sell | 1,000 | $71.53 | $71.5K | 26,762 |
| Sep 14, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $70.79 | $35.4K | 73,924 |
| Sep 1, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $72.80 | $207.5K | 171,843 |
| Aug 26, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 5,400 | $74.30 | $401.2K | 344,489 |
| Aug 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $75.48 | $37.7K | 74,424 |
| Aug 11, 2026 | Gutwerg Ori | officer: SVP, GENERICS | Sell | 3,162 | $77.00 | $243.5K | 75,534 |
| Jul 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $81.36 | $231.9K | 174,693 |
| Jul 14, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $81.84 | $40.9K | 77,390 |
| Jul 6, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 3,313 | $86.00 | $284.9K | 177,543 |
| Jun 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $84.12 | $239.7K | 177,543 |
| Jun 15, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $82.03 | $41.0K | 77,890 |
| Jun 10, 2026 | HAUGHEY THOMAS | director | Sell | 2,000 | $80.88 | $161.8K | 38,878 |
| Jun 9, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 3,312 | $80.00 | $265.0K | 180,393 |
| May 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $78.16 | $39.1K | 78,390 |
| May 13, 2026 | Gutwerg Ori | officer: SVP, GENERICS | Sell | 2,772 | $79.50 | $220.4K | 78,696 |
| May 13, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 55,000 | $77.57 | $4.27M | 349,889 |
| May 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $79.21 | $36.4K | 38,271 |
| May 13, 2026 | Walsh Patrick D | director | Sell | 13,973 | $80.66 | $1.13M | 48,432 |
| Apr 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $77.95 | $39.0K | 78,890 |
| Mar 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36.3K | 79,390 |
| Mar 13, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 3,162 | $71.64 | $226.5K | 91,309 |
| Mar 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 | $74.91 | $357.5K | 38,730 |
| Mar 10, 2026 | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 6,572 | $74.33 | $488.5K | 57,033 |
| Mar 10, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,723 | $74.19 | $424.6K | 101,387 |
| Mar 5, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 7,312 | $75.50 | $552.0K | 189,543 |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 0 |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 0 |
| Feb 17, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,277 | $77.01 | $406.4K | 0 |
| Feb 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,813 | $77.02 | $293.7K | 0 |
| Feb 12, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,470 | $77.04 | $190.3K | 0 |
| Feb 12, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 3,325 | $77.04 | $256.2K | 0 |
| Feb 12, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 3,663 | $77.04 | $282.2K | 0 |
| Feb 12, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 21,986 | $77.01 | $1.69M | 0 |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 12,608 | $76.74 | $967.6K | 0 |
| Feb 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,051 | $77.00 | $80.9K | 0 |
| Feb 11, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,503 | $76.25 | $419.6K | 0 |
| Feb 11, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,011 | $76.25 | $229.6K | 0 |
| Feb 11, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,017 | $76.25 | $230.0K | 0 |
| Feb 11, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 4,269 | $76.25 | $325.5K | 0 |
| Feb 11, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 4,267 | $76.25 | $325.4K | 0 |
| Feb 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 30,659 | $76.25 | $2.34M | 0 |
| Feb 11, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,546 | $76.25 | $346.6K | 0 |
| Feb 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,762 | $76.25 | $134.4K | 0 |
| Feb 11, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,898 | $76.25 | $221.0K | 0 |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 0 |
Showing 1–50 of 245
1 / 5
ANIP Insider Buying Activity
The following table shows recent insider purchases of ANI Pharmaceuticals, Inc. (ANIP) stock reported via SEC Form 4 filings.
No insider buying activity found for ANIP in the last 12 months.
ANIP Insider Selling Activity
The following table shows recent insider sales of ANI Pharmaceuticals, Inc. (ANIP) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $72.87 | $207.7K | 166,143 |
| Oct 16, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 5,400 | $71.89 | $388.2K | 333,689 |
| Oct 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $73.59 | $36.8K | 73,424 |
| Sep 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $73.00 | $208.1K | 168,993 |
| Sep 16, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 5,400 | $71.00 | $383.4K | 339,089 |
| Sep 14, 2026 | Thoma Jeanne | director | Sell | 1,000 | $71.53 | $71.5K | 26,762 |
| Sep 14, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $70.79 | $35.4K | 73,924 |
| Sep 1, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $72.80 | $207.5K | 171,843 |
| Aug 26, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 5,400 | $74.30 | $401.2K | 344,489 |
| Aug 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $75.48 | $37.7K | 74,424 |
| Aug 11, 2026 | Gutwerg Ori | officer: SVP, GENERICS | Sell | 3,162 | $77.00 | $243.5K | 75,534 |
| Jul 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $81.36 | $231.9K | 174,693 |
| Jul 14, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $81.84 | $40.9K | 77,390 |
| Jul 6, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 3,313 | $86.00 | $284.9K | 177,543 |
| Jun 30, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 2,850 | $84.12 | $239.7K | 177,543 |
| Jun 15, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $82.03 | $41.0K | 77,890 |
| Jun 10, 2026 | HAUGHEY THOMAS | director | Sell | 2,000 | $80.88 | $161.8K | 38,878 |
| Jun 9, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 3,312 | $80.00 | $265.0K | 180,393 |
| May 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $78.16 | $39.1K | 78,390 |
| May 13, 2026 | Gutwerg Ori | officer: SVP, GENERICS | Sell | 2,772 | $79.50 | $220.4K | 78,696 |
| May 13, 2026 | Lalwani Nikhil | director, officer: PRESIDENT & CEO | Sell | 55,000 | $77.57 | $4.27M | 349,889 |
| May 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 | $79.21 | $36.4K | 38,271 |
| May 13, 2026 | Walsh Patrick D | director | Sell | 13,973 | $80.66 | $1.13M | 48,432 |
| Apr 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $77.95 | $39.0K | 78,890 |
| Mar 13, 2026 | Cook Meredith | officer: SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $72.62 | $36.3K | 79,390 |
| Mar 13, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 3,162 | $71.64 | $226.5K | 91,309 |
| Mar 13, 2026 | Rowland Thomas Andrew | officer: SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 | $74.91 | $357.5K | 38,730 |
| Mar 10, 2026 | Davis Krista | officer: SVP, CHIEF HR OFFICER | Sell | 6,572 | $74.33 | $488.5K | 57,033 |
| Mar 10, 2026 | Mutz Christopher | officer: HEAD OF RARE DISEASE | Sell | 5,723 | $74.19 | $424.6K | 101,387 |
| Mar 5, 2026 | CAREY STEPHEN P. | officer: SVP & CFO | Sell | 7,312 | $75.50 | $552.0K | 189,543 |
| Feb 20, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 5,323 | $78.02 | $415.3K | 0 |
| Feb 19, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,814 | $77.74 | $296.5K | 0 |
| Feb 17, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,277 | $77.01 | $406.4K | 0 |
| Feb 12, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,813 | $77.02 | $293.7K | 0 |
| Feb 12, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 2,470 | $77.04 | $190.3K | 0 |
| Feb 12, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 3,325 | $77.04 | $256.2K | 0 |
| Feb 12, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 3,663 | $77.04 | $282.2K | 0 |
| Feb 12, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 21,986 | $77.01 | $1.69M | 0 |
| Feb 12, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 12,608 | $76.74 | $967.6K | 0 |
| Feb 12, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,051 | $77.00 | $80.9K | 0 |
| Feb 11, 2026 | CAREY STEPHEN P. | SVP & CFO | Sell | 5,503 | $76.25 | $419.6K | 0 |
| Feb 11, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 3,011 | $76.25 | $229.6K | 0 |
| Feb 11, 2026 | Davis Krista | SVP, CHIEF HR OFFICER | Sell | 3,017 | $76.25 | $230.0K | 0 |
| Feb 11, 2026 | Gassert Chad | SVP - CORP. DEV. & STRATEGY | Sell | 4,269 | $76.25 | $325.5K | 0 |
| Feb 11, 2026 | Gutwerg Ori | SVP, GENERICS | Sell | 4,267 | $76.25 | $325.4K | 0 |
| Feb 11, 2026 | Lalwani Nikhil | PRESIDENT & CEO | Sell | 30,659 | $76.25 | $2.34M | 0 |
| Feb 11, 2026 | Mutz Christopher | HEAD OF RARE DISEASE | Sell | 4,546 | $76.25 | $346.6K | 0 |
| Feb 11, 2026 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell | 1,762 | $76.25 | $134.4K | 0 |
| Feb 11, 2026 | Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS | Sell | 2,898 | $76.25 | $221.0K | 0 |
| Jan 13, 2026 | Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 | $84.33 | $42.2K | 0 |
ANIP Insiders
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
Bought $138.3KSold $59.00M
29 tradesLast: Feb 11, 2026
Similar Stocks to ANIP
ELAN
Elanco Animal Health Incorporated
$23.06-0.88%
$11.52B
AMRX
Amneal Pharmaceuticals, Inc.
$21.51+0.28%
$6.87B
INDV
Indivior Pharmaceuticals Inc
$35.37+0.99%
$4.41B
PCRX
Pacira BioSciences, Inc.
$36.40+0.03%
$1.45B
ETON
Eton Pharmaceuticals, Inc.
$52.18-2.78%
$1.43B
HROW
Harrow Health, Inc.
$28.28-5.70%
$1.09B
AMPH
Amphastar Pharmaceuticals, Inc.
$27.43+1.93%
$1.09B
AQST
Aquestive Therapeutics, Inc.
$3.88-3.84%
$507.1M